Moe Alsumidaie

http://Moe%20Alsumidaie
Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.

Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Approval FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression

The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

GLP-1 Trials Have an Imaging Problem | Prof. Mikael Boesen, MSK Radiology

  • By Moe Alsumidaie
  • April 20, 2026

Previous post
Interview with Northwell Health’s Christina Brennan
Next post
Standardizing on the Veeva Vault Platform

Latest News

  • VK2735 Moves 75% of Patients Down BMI Category in 13 Weeks 01
    News

    VK2735 Moves 75% of Patients Down BMI Category in 13 Weeks

    November 16, 2026
  • Clinical research sites cite trial complexity as top operational challenge 02
    News

    Clinical research sites cite trial complexity as top operational challenge

    November 15, 2026
  • Tovorafenib shows 50.9-month median time to next treatment in pediatric low-grade glioma 03
    News

    Tovorafenib shows 50.9-month median time to next treatment in pediatric low-grade glioma

    November 15, 2026
  • CagriSema Achieves 21% Average Weight Loss at Lower Doses in Phase 3 Trial 04
    News

    CagriSema Achieves 21% Average Weight Loss at Lower Doses in Phase 3 Trial

    November 15, 2026
  • Lilly presents obesity drug data at ObesityWeek 2026 05
    News

    Lilly presents obesity drug data at ObesityWeek 2026

    November 15, 2026
  • FDA Lifts Clinical Hold on Aardvark's ARD-101 for PWS Hyperphagia 06
    News

    FDA Lifts Clinical Hold on Aardvark’s ARD-101 for PWS Hyperphagia

    November 15, 2026
The Clinical Trial Vanguard
  • ABOUT US
  • Log In
  • Membership Account
    • Membership Billing
    • Membership Cancel
    • Membership Orders
    • Your Profile
  • Membership Checkout
    • Membership Confirmation
  • Membership Levels
  • PRIVACY POLICY
  • SUBSCRIBE
  • TERMS AND CONDITIONS OF ACCESS AND USE
Copyright © 2026 The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Start typing and press Enter to search

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}